Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 7% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price fell 7% on Monday . The company traded as low as $18.34 and last traded at $18.58. 72,167 shares traded hands during trading, a decline of 70% from the average session volume of 241,564 shares. The stock had previously closed at $19.99.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on DNTH shares. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Guggenheim reissued a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and an average target price of $54.33.

Dianthus Therapeutics Price Performance

The firm has a market capitalization of $589.78 million, a PE ratio of -7.35 and a beta of 1.82. The firm’s fifty day moving average is $21.91 and its two-hundred day moving average is $24.24.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. As a group, equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $26,000. Quest Partners LLC lifted its position in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after acquiring an additional 1,124 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth $33,000. KBC Group NV purchased a new position in shares of Dianthus Therapeutics in the fourth quarter valued at $35,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at $59,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.